SynthesisCNS neuroscience & therapeutics2026
Association of Circulating Tumor DNA With Brain Metastases: A Systematic Review and Meta-Analysis.
Synthesis in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBrain metastases are a major contributor to morbidity and mortality in patients with advanced solid tumors; however, early detection and accurate prognostic assessment remain significant clinical challenges. ctDNA is a minimally invasive biomarker that allows real-time monitoring of tumor behavior and provides information on systemic tumor burden and molecular diversity. This study aimed to systematically evaluate the diagnostic and prognostic value of ctDNA in brain metastases, with particular emphasis on the complementary roles of plasma and CSF ctDNA.
methodsPubMed, Embase, Cochrane Library, Web of Science, and ScienceDirect were systematically searched up to January 2025. Pooled ORs, SMDs, and HRs with 95% CIs were calculated using fixed-effects or random-effects models according to heterogeneity.
resultsFifteen studies (N = 1763) were included. ctDNA positivity was significantly associated with increased risk of brain metastases (OR = 1.67, 95% CI: 1.24-2.26, p = 0.001). Subgroup analysis showed that NGS had notably higher predictive performance (OR = 5.50, 95% CI: 1.92-15.76, p = 0.002). Plasma ctDNA levels were significantly higher in patients with brain metastases (SMD = 0.51, 95% CI: 0.18-0.84, p = 0.002). Notably, CSF ctDNA positivity was strongly associated with worse overall survival (HR = 2.75, 95% CI: 1.75-4.32, p < 0.001).
conclusionPlasma ctDNA serves as a non-invasive biomarker for systemic metastatic risk, whereas CSF ctDNA provides superior prognostic value for intracranial disease. Using these biomarkers together in a clinical workflow could enhance risk assessment and guide treatment decisions in patients with brain metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.